177 related articles for article (PubMed ID: 29648492)
21. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Inoue A; Kawakami C; Takitani K; Tamai H
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e322-4. PubMed ID: 24608072
[TBL] [Abstract][Full Text] [Related]
22. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
Sallman DA
Haematologica; 2020 Jun; 105(6):1470-1472. PubMed ID: 32482751
[No Abstract] [Full Text] [Related]
23. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.
McGraw KL; Nguyen J; Komrokji RS; Sallman D; Al Ali NH; Padron E; Lancet JE; Moscinski LC; List AF; Zhang L
Haematologica; 2016 Aug; 101(8):e320-3. PubMed ID: 27081179
[No Abstract] [Full Text] [Related]
24. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with
Ciurea SO; Chilkulwar A; Saliba RM; Chen J; Rondon G; Patel KP; Khogeer H; Shah AR; Randolph BV; Perez JMR; Popat U; Hosing CM; Bashir Q; Mehta R; Al-Atrash G; Im J; Khouri IF; Kebriaei P; Champlin RE
Blood; 2018 Jun; 131(26):2989-2992. PubMed ID: 29769261
[No Abstract] [Full Text] [Related]
25. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
[No Abstract] [Full Text] [Related]
26. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
27. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
29. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow leukaemic transformation of myelodysplastic syndrome revealed by a cutaneous Langerhans cell infiltrate: partial response to azacitidine.
Osio A; Elfatoiki F; Raffoux E; Vignon-Pennamen MD; de Labarthe A; Cordoliani F; Petrella T; Bagot M; Janin A; Battistella M; Bouaziz JD
Eur J Dermatol; 2013; 23(5):710-1. PubMed ID: 24125873
[No Abstract] [Full Text] [Related]
31. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and
Martin-Cabrera P; Jeromin S; Perglerovà K; Haferlach C; Kern W; Haferlach T
Haematologica; 2017 Apr; 102(4):e125-e128. PubMed ID: 28057736
[No Abstract] [Full Text] [Related]
33. The Problem of TP53-Mutant MDS/AML.
Sallman DA
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S65-S66. PubMed ID: 32862873
[No Abstract] [Full Text] [Related]
34. MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.
Krejcik Z; Belickova M; Hrustincova A; Votavova H; Jonasova A; Cermak J; Dyr JE; Merkerova MD
Cancer Biomark; 2018; 22(1):101-110. PubMed ID: 29630523
[TBL] [Abstract][Full Text] [Related]
35. Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation.
Sumi M; Kitahara M; Shishido T; Kazumoto H; Uematsu N; Kirihara T; Sato K; Ueki T; Hiroshima Y; Kobayashi H
Intern Med; 2020 Nov; 59(21):2763-2767. PubMed ID: 32641650
[TBL] [Abstract][Full Text] [Related]
36. Necrotizing fasciitis in myelodysplastic syndrome: an exceptionally rare occurrence.
Niscola P; Tendas A; Cupelli L; Neri B; Scaramucci L; Morino L; Giovannini M; Fratoni S; de Fabritiis P
Support Care Cancer; 2013 Feb; 21(2):365-6. PubMed ID: 22960853
[No Abstract] [Full Text] [Related]
37. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
[TBL] [Abstract][Full Text] [Related]
38. Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group.
Drozd-Sokołowska J; Gil L; Waszczuk-Gajda A; Mądry K; Piekarska A; Dutka M; Basak GW; Karakulska-Prystupiuk E; Dwilewicz-Trojaczek J
Transplant Proc; 2016 Jun; 48(5):1802-5. PubMed ID: 27496495
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
40. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
